Related Experiment Video
Updated: Aug 13, 2026

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
Published on: July 29, 2014
RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with
Frédéric Simonin1, Martine Schmitt, Jean-Paul Laulin
1Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique/Institut National de la Santé et de la Recherche Médicale/Universite Louis Pasteur, 67404 Illkirch Cedex, France. simonin@esbs.u-strasbg.fr
Abstract:
Neuropeptide FF (NPFF) has been proposed to play a role in pain modulation, opioid tolerance, and several other physiological processes. However, pharmacological agents that would help define physiological roles for this peptide are still missing. Here we report the discovery of a potent and selective NPFF receptor antagonist, RF9, that can be administered systemically. This compound does not show any effects by itself but can block efficiently the increase in blood pressure and heart rate evoked by NPFF. When chronically coinjected with heroin, RF9 completely blocks the delayed and long-lasting paradoxical opioid-induced hyperalgesia and prevents the development of associated tolerance. Our data indicate that NPFF receptors are part of a bona fide antiopioid system and that selective antagonists of these receptors could represent useful therapeutic agents for improving the efficacy of opioids in chronic pain treatment.
Related Concept Videos
Analgesia and Pain Management
Opioid Receptors: Overview
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Opioid Analgesics: Morphine and Other Natural Cogeners
Desensitization and Tachyphylaxis
Several...
